Alterity Therapeutics Limited (ATHE)
Automate Your Wheel Strategy on ATHE
With Tiblio's Option Bot, you can configure your own wheel strategy including ATHE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ATHE
- Rev/Share 0.0009
- Book/Share 0.0015
- PB 7.1601
- Debt/Equity 0.0136
- CurrentRatio 3.8381
- ROIC -3.4165
- MktCap 96638726.8896
- FreeCF/Share -0.0037
- PFCF -5.0736
- PE -2.1361
- Debt/Assets 0.01
- DivYield 0
- ROE -2.4182
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ATHE | The Benchmark Company | Speculative Buy | Hold | -- | -- | Feb. 3, 2025 |
| Initiation | ATHE | Maxim Group | -- | Buy | -- | $8 | Dec. 12, 2024 |
News
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity, will participate in a Fireside Chat hosted by MST Access on Wednesday, 25 June 2025 in Australia / Tuesday, 24 June 2025 in the United States. Dr. Stamler will provide a corporate update with a focus on the progress made on the ATH434 development program in Multiple System Atrophy since the Company released positive Phase 2 …
Read More
Alterity Therapeutics Prominently Featured at the International MSA Congress
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows higher α- synuclein concentration is associated with greater burden of orthostatic symptoms – MELBOURNE, Australia and SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that several oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) were featured at the 2025 International MSA …
Read More
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations related to Alterity's clinical programs in Multiple System Atrophy (MSA) will be featured at the 2025 International MSA Congress taking place May 9 - 11, 2025 in Boston, MA, USA. The Congress is presented by Mission MSA, a non-profit organization dedicated to improving the quality of life and building hope for people affected by MSA through support services, educational …
Read More
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy Phase 2 data featured in an oral presentation at the American Academy of Neurology Annual Meeting ATH434-202 open-label trial in advanced MSA completed in March 2025 Cash balance on 31 March 2025 of A$17.96M with an additional A$27.1M raised subsequent to the end of the quarter MELBOURNE, Australia and SAN FRANCISCO, April 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for …
Read More
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer presented the ATH434-201 Phase 2 clinical trial results at the annual MSA Research Symposium hosted by University College London, Institute of Neurology in partnership with the MSA Trust of the U.K.
Read More
About Alterity Therapeutics Limited (ATHE)
- IPO Date 2003-09-29
- Website https://alteritytherapeutics.com
- Industry Biotechnology
- CEO Dr. David A. Stamler M.D.
- Employees 10